Literature DB >> 21163595

The effect of synthetic genistein on menopause symptom management in healthy postmenopausal women: a multi-center, randomized, placebo-controlled study.

Malkanthi Evans1, James G Elliott, Prachi Sharma, Robert Berman, Najla Guthrie.   

Abstract

OBJECTIVE: To evaluate the efficacy of synthetic genistein for reducing the frequency and severity of hot flushes. STUDY
DESIGN: A 12 week randomized double-blind, placebo-controlled study in which 84 postmenopausal women received placebo or a single 30 mg dose of synthetic genistein. Outcome measures primary: percentage change in the number of daily hot flushes from pre-treatment to week 12. Secondary: duration and severity of daily hot flushes, Greene Climacteric Scale score, serum follicle stimulating hormone (FSH), 17β-estradiol and endometrial thickness.
RESULTS: Genistein supplemented subjects completing at least 4 weeks on trial (n=40) demonstrated a 51% reduction (9.4-4.7/day) in the number of hot flushes by week 12 compared to a 27% reduction in the placebo group (9.9-7.1/day) (p=0.026). Subjects in the genistein group also reported significantly fewer hot flushes per day (p=0.010) and a decrease in total duration of hot flushes per day (p=0.009) at week 12 versus placebo. Subjects on genistein (n=32) completing 12 weeks on trial demonstrated a 51% reduction (9.7-4.7/day) in the number of hot flushes by week 12 (p=0.049) compared to 30% reduction in the placebo group (9.8-7.0/day) and had fewer hot flushes per day and a decrease in total duration of hot flushes per day at week 12 compared to placebo (p=0.020 and p=0.017, respectively). There were no differences between groups in Greene Climacteric Scale, FSH, 17β-estradiol, endometrial thickness or adverse events.
CONCLUSIONS: The current study provides the first evidence that a single daily dose of 30 mg of synthetic genistein reduces hot flush frequency and duration. Copyright Â
© 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21163595     DOI: 10.1016/j.maturitas.2010.11.012

Source DB:  PubMed          Journal:  Maturitas        ISSN: 0378-5122            Impact factor:   4.342


  23 in total

1.  Inhibition of genistein glucuronidation by bisphenol A in human and rat liver microsomes.

Authors:  Janis L Coughlin; Paul E Thomas; Brian Buckley
Journal:  Drug Metab Dispos       Date:  2011-12-06       Impact factor: 3.922

Review 2.  Effects of isoflavones and amino acid therapies for hot flashes and co-occurring symptoms during the menopausal transition and early postmenopause: a systematic review.

Authors:  Annette J Thomas; Rita Ismail; Lisa Taylor-Swanson; Lori Cray; Janet G Schnall; Ellen Sullivan Mitchell; Nancy Fugate Woods
Journal:  Maturitas       Date:  2014-05-28       Impact factor: 4.342

3.  Safety and feasibility of estrogen receptor-β targeted phytoSERM formulation for menopausal symptoms: phase 1b/2a randomized clinical trial.

Authors:  Lon S Schneider; Gerson Hernandez; Liqin Zhao; Adrian A Franke; Yu-Ling Chen; Sonia Pawluczyk; Wendy J Mack; Roberta D Brinton
Journal:  Menopause       Date:  2019-08       Impact factor: 2.953

4.  Quantitative efficacy of soy isoflavones on menopausal hot flashes.

Authors:  Lujin Li; Yinghua Lv; Ling Xu; Qingshan Zheng
Journal:  Br J Clin Pharmacol       Date:  2015-04       Impact factor: 4.335

Review 5.  Evaluation of the potential antidepressant effects of soybean isoflavones.

Authors:  Mark Messina; Carey Gleason
Journal:  Menopause       Date:  2016-12       Impact factor: 2.953

6.  Effects of a dietary intervention and weight change on vasomotor symptoms in the Women's Health Initiative.

Authors:  Candyce H Kroenke; Bette J Caan; Marcia L Stefanick; Garnet Anderson; Robert Brzyski; Karen C Johnson; Erin LeBlanc; Cathy Lee; Andrea Z La Croix; Hannah Lui Park; Stacy T Sims; Mara Vitolins; Robert Wallace
Journal:  Menopause       Date:  2012-09       Impact factor: 2.953

7.  Evaluation of CYP450 inhibitory effects and steady-state pharmacokinetics of genistein in combination with cholecalciferol and citrated zinc bisglycinate in postmenopausal women.

Authors:  Bruce P Burnett; Lakshmi Pillai; Alessandra Bitto; Francesco Squadrito; Robert M Levy
Journal:  Int J Womens Health       Date:  2011-05-09

8.  The role of nutraceuticals in chemoprevention and chemotherapy and their clinical outcomes.

Authors:  Sabita N Saldanha; Trygve O Tollefsbol
Journal:  J Oncol       Date:  2011-12-07       Impact factor: 4.375

Review 9.  Genistein: An Integrative Overview of Its Mode of Action, Pharmacological Properties, and Health Benefits.

Authors:  Javad Sharifi-Rad; Cristina Quispe; Muhammad Imran; Abdur Rauf; Muhammad Nadeem; Tanweer Aslam Gondal; Bashir Ahmad; Muhammad Atif; Mohammad S Mubarak; Oksana Sytar; Oxana Mihailovna Zhilina; Ekaterina Robertovna Garsiya; Antonella Smeriglio; Domenico Trombetta; Daniel Gabriel Pons; Miquel Martorell; Susana M Cardoso; Ahmad Faizal Abdull Razis; Usman Sunusi; Ramla Muhammad Kamal; Lia Sanda Rotariu; Monica Butnariu; Anca Oana Docea; Daniela Calina
Journal:  Oxid Med Cell Longev       Date:  2021-07-19       Impact factor: 6.543

10.  Genistein in 1:1 inclusion complexes with ramified cyclodextrins: theoretical, physicochemical and biological evaluation.

Authors:  Corina Danciu; Codruta Soica; Mircea Oltean; Stefana Avram; Florin Borcan; Erzsebet Csanyi; Rita Ambrus; Istvan Zupko; Delia Muntean; Cristina A Dehelean; Marius Craina; Ramona A Popovici
Journal:  Int J Mol Sci       Date:  2014-01-27       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.